Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS, FVT

PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference


INCLINE VILLAGE, Nev., Nov. 19, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare Conference in New York City.  The session will be webcast live and will occur on Tuesday, November 27, 2018, at 1:50 p.m. EST.

To access the live and subsequently archived webcast of the presentation, visit the Company's website at pdl.com and go to the Investor Relations section and select "Events & Presentations."  Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.  The archived webcast will be available for at least seven days following the presentation. 

About PDL BioPharma, Inc.

We seek to provide a significant return for our stockholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. In 2012 we began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016 we began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, we have consummated 17 of such transactions, of which nine are active and outstanding. We have one debt transaction outstanding, representing deployed capital of $20.0 million: CareView; we have one hybrid royalty/debt transaction outstanding, representing deployed capital of $44.0 million: Wellstat Diagnostics; and we have five royalty transactions outstanding, representing deployed capital of $416.1 million, respectively: KYBELLA®, AcelRx, University of Michigan, Viscogliosi Brothers and Assertio Therapeutics (formerly Depomed). Our equity and loan investments in the Noden Products represent deployed capital of $191.2 million, respectively, and our converted equity and loan investment in LENSAR represents deployed capital of $40.0 million.

NOTE:  PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all rights therein.

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)

 

SOURCE PDL BioPharma, Inc.


These press releases may also interest you

at 09:00
Guidewire announced that Guidewire PartnerConnect Consulting and Global Premier partner, Ernst & Young LLP (EY), has achieved the global Migration Acceleration Specialization. Partners who have earned this specialization have demonstrated the...

at 09:00
The Commerce Casino & Hotel, home to the largest poker room in the world, proudly announces an exciting partnership with the richest, most prestigious, and longest-running poker series ? the World Series of Poker® (WSOP®). This collaboration...

at 09:00
The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp , a global leader of innovative diagnostic and biopharma laboratory services, to serve as its...

at 09:00
Rex 3 recently opened its doors to students from Florida Atlantic University (FAU) for Rex 3's 11th Annual 101 Printing Tour, reinforcing its commitment to community engagement and education in the printing industry. This tour provided students with...

at 09:00
GigaMedia Limited today announced its unaudited financial results for the fourth quarter and full year of 2023. Highlights For 2023, GigaMedia reported revenues of $4.3 million, with a gross profit of $2.4 million, an operating loss of $3.2 million...

at 09:00
Yardi® is proud to sponsor the 2024 Manufactured Housing Institute (MHI) Congress & Expo, April 3-4, at the iconic MGM Grand in Las Vegas. At the exhibit hall attendees can explore the newest product innovations, accessible April 3, from 1 p.m. to...



News published on and distributed by: